BARDA is partnering with VitalConnect to assess the ability of a wearable device to remotely monitor individuals during the COVID-19 outbreak for changes in health deterioration, including but not limited to respiratory rate, body temperature, blood oxygen levels (SpO2) and heart arrhythmias, to improve patient outcomes. Nursing home patients, an at-risk population, will be continuously monitored for early indication of changes in health status or potentially inform on COVID-19 infection. In addition, in a separate cohort, COVID-19 patients will be monitored to determine any changes in health, including QT interval changes which may require an escalation in care.
The elderly and individuals with underlying medical conditions may be at higher risk for severe complications from COVID-19. Early indication of patient deterioration or cardiac arrhythmia will allow healthcare professionals to intervene earlier in order to improve clinical management of patients and health outcomes. These pilot clinical studies will be conducted as part of quality improvement to support use of these remote monitoring technologies as adjunctive diagnostic health support.
The Vista Solution incorporates four primary components; The VitalPatch clinical grade biosensor, a Vista Tablet, the VitalCloud, and the VistaCenter central monitoring station. Through the Vista Solution, clinicians can monitor up to 11 different patient vitals in real-time including those captured by the VitalPatch (single-lead EKG, heart rate, heart rate variability, respiratory rate, body temperature, body posture, fall detection, activity) and those captured by 3rd party devices (blood oxygen, weight, blood pressure). COVID-19 patients suffer from a variety of symptoms including respiratory distress, low blood oxygen levels, and cardiac arrhythmia, which can all be monitored with the Vista Solution.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
About the Company:
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. For more information: www.vitalconnect.com.